Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996–98 and 2006–09

References

• Lenssinck ML, Burdorf A, Boonen A, Gignac MA, Hazes JM, Luime JJ. Consequences of inflammatory arthritis for workplace productivity loss and sick leave: a systematic review. Ann Rheum Dis 2013;72:493–505.
   PubMed Web of Science ®Google Scholar
• Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology ( Oxford) 2004;43:1374–82.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol 2007;21:929–42.
   PubMed Web of Science ®Google Scholar
• Gulfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden. Ann Rheum Dis 2010;69:352–7.
   PubMed Web of Science ®Google Scholar
• Hallert E, Husberg M, Kalkan A, Skogh T, Bernfort L. Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project. Scand J Rheumatol 2014;43:177–83.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, Van Der Heijde D, Emery P, Bathon JM. Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716–22.
   PubMed Web of Science ®Google Scholar
• Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008;35:206–15.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum 2009;61:1592–600.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, nonblinded, parallel-group Swefot trial. Lancet 2012;379:1712–20.
   PubMed Web of Science ®Google Scholar
• Kalkan A, Hallert E, Bernfort L, Husberg M, Carlsson P. Costs of rheumatoid arthritis during the period 1990–2010: a register-based cost-of-illness study in Sweden. Rheumatology ( Oxford) 2014;53:153–60.
   PubMed Web of Science ®Google Scholar
• Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen M, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Ann Rheum Dis 2014;73:1954–61.
   PubMed Web of Science ®Google Scholar
• Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology ( Oxford) 2006;45: 325–31.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Prevoo MLL, van´t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44–8.
   PubMed Web of Science ®Google Scholar
• Ekdahl C, Eberhardt KB, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Scand J Rheumatol 1998;17:263–71.
   Google Scholar
• The EuroQol group. The EuroQol-- a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? Bmj BMJ 2000;320:1197–200.
   PubMed Web of Science ®Google Scholar
• Sokka T. Increases in use of methotrexate since the 1980s. Clin Exp Rheumatol 2010:S13–20. 2010;28(Suppl 61):S13-20.
   Google Scholar
• Petersson IF. Team care.Traditions and new trends. J Rheumatol 2006;33:1895–6.
   PubMed Web of Science ®Google Scholar
• Nikiphorou E, Davies C, Mugford M, Cooper N, Brooksby A, Bunn DK, et al. Direct health costs of inflammatory polyarthritis 10 years after disease onset: results from the Norfolk arthritis register. J Rheumatol 2015;42:794–8.
   PubMed Web of Science ®Google Scholar
• Nikiphorou E, Carpenter L, Morris S, Macgregor AJ, Dixey J, Kiely P, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. Arthritis Rheumatol 2014;66:1081–9.
   PubMed Web of Science ®Google Scholar
• Hekmat K, Jacobsson L, Nilsson JA, Petersson IF, Robertsson O, Garellick G, et al. Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis - results from a well defined population in south Sweden. Arthritis Res Ther 2011;13:R67.
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625–39.
   PubMed Web of Science ®Google Scholar
• Aga AB, Lie E, Uhlig T, Olsen IC, Wierød A, Kalstad S, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis 2015;74:381–8.
   PubMed Web of Science ®Google Scholar
• Visser K, Van Der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009;68:1094–9.
   PubMed Web of Science ®Google Scholar
• Kirchhoff T, Ruof J, Mittendorf T, Rihl M, Bernateck M, Mau W, et al. Cost of illness in rheumatoid arthritis in Germany in 1997–98 and 2002: cost drivers and cost savings. Rheumatology ( Oxford) 2011;50:756–61.
   PubMed Web of Science ®Google Scholar
• Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010–14.
   PubMed Web of Science ®Google Scholar
• Puolakka K, Kautiainen H, Pekurinen M, Möttönen T, Hannonen P, Korpela M, et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients’ sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis 2006;65:899–904.
   PubMed Web of Science ®Google Scholar
• Neovius M, Simard JF, Askling J; ARTIS Study Group. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop?. Ann Rheum Dis 2011;70:1010–15.
   PubMed Web of Science ®Google Scholar
• Dadoun S, Guillemin F, Lucier S, Looten V, Saraux A, Berenbaum F, et al. Work productivity loss in early arthritis during the first 3 years of disease: a study from a French National Multicenter Cohort. Arthritis Care Res 2014;66:1310–18.
   Web of Science ®Google Scholar
• Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A; German Collaborative Arthritis Centres. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175–83.
   PubMed Web of Science ®Google Scholar
• Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27:S118–23.
   PubMed Web of Science ®Google Scholar
• Eriksson JK, Johansson K, Askling J, Neovius M. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed? Ann Rheum Dis 2015;74:648–54.
   PubMed Web of Science ®Google Scholar
• Neovius M, Simard JF, Askling J; ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011;70:624–9.
   PubMed Web of Science ®Google Scholar
• Kalkan A, Roback K, Hallert E, Carlsson P. Factors influencing rheumatologists’ prescription of biological treatment in rheumatoid arthritis: an interview study. Implement Sci 2014;11:153–5.
   Web of Science ®Google Scholar